stoxline Quote Chart Rank Option Currency Glossary
  
Catalyst Pharmaceuticals, Inc. (CPRX)
21.03  -0.42 (-1.96%)    07-18 16:00
Open: 21.64
High: 21.64
Volume: 1,141,903
  
Pre. Close: 21.45
Low: 20.985
Market Cap: 2,565(M)
Technical analysis
2025-07-18 4:40:12 PM
Short term     
Mid term     
Targets 6-month :  27.48 1-year :  29.59
Resists First :  23.53 Second :  25.34
Pivot price 21.38
Supports First :  20.61 Second :  17.14
MAs MA(5) :  21.24 MA(20) :  21.54
MA(100) :  23.05 MA(250) :  21.8
MACD MACD :  -0.7 Signal :  -0.7
%K %D K(14,3) :  40.8 D(3) :  37.5
RSI RSI(14): 38
52-week High :  26.57 Low :  15.34
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CPRX ] has closed above bottom band by 24.0%. Bollinger Bands are 61% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 21.66 - 21.79 21.79 - 21.9
Low: 20.7 - 20.84 20.84 - 20.96
Close: 20.84 - 21.05 21.05 - 21.25
Company Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Headline News

Thu, 17 Jul 2025
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Wed, 16 Jul 2025
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance

Tue, 08 Jul 2025
Institutional investors in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) lost 3.5% last week but have reaped the benefits of longer-term growth - simplywall.st

Mon, 07 Jul 2025
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Nasdaq

Fri, 04 Jul 2025
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance

Thu, 19 Jun 2025
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 122 (M)
Shares Float 115 (M)
Held by Insiders 6.2 (%)
Held by Institutions 83.1 (%)
Shares Short 7,730 (K)
Shares Short P.Month 7,430 (K)
Stock Financials
EPS 1.57
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.51
Profit Margin 36.9 %
Operating Margin 44.8 %
Return on Assets (ttm) 18.5 %
Return on Equity (ttm) 29.1 %
Qtrly Rev. Growth 43.5 %
Gross Profit (p.s.) 3.66
Sales Per Share 4.38
EBITDA (p.s.) 2.2
Qtrly Earnings Growth 136.8 %
Operating Cash Flow 268 (M)
Levered Free Cash Flow 223 (M)
Stock Valuations
PE Ratio 13.39
PEG Ratio 0
Price to Book value 3.23
Price to Sales 4.79
Price to Cash Flow 9.57
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android